# ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

> **NCT01921335** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 41 (actual)

## Conditions studied

- Brain Metastases From HER2 and Breast Cancer
- Advanced HER2-positive Breast Cancer

## Interventions

- **DRUG:** ARRY-380 Twice Daily Dosage
- **DRUG:** ARRY-380 Once Daily
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01921335
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2018-03
- **Final completion:** 2023-12-31
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-11-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01921335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01921335, "ARRY-380 + Trastuzuamab for Breast w/ Brain Mets". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01921335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*